NasdaqGM - Delayed Quote USD

Keros Therapeutics, Inc. (KROS)

Compare
60.30 -0.95 (-1.55%)
At close: 4:00 PM EDT
60.30 0.00 (0.00%)
After hours: 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Jasbir S. Seehra Ph.D. CEO & Chair of the Board 1.13M 158.64k 1956
Mr. Christopher Rovaldi M.Sc. President & COO 784.9k -- 1974
Mr. Keith C. Regnante MBA Chief Financial Officer 636.11k 1.22M 1970
Ms. Esther Cho J.D. Senior VP, General Counsel & Secretary -- -- --
Ms. Robin Wagner Senior Vice President of Human Resources -- -- --
Mr. John Oram M.B.A. Senior Vice President of Program & Portfolio Management -- -- --

Keros Therapeutics, Inc.

1050 Waltham Street
Suite 302
Lexington, MA 02421
United States
617 314 6297 https://www.kerostx.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
149

Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Keros Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 4, 2024 at 1:30 PM UTC - November 8, 2024 at 1:30 PM UTC

Keros Therapeutics, Inc. Earnings Date

Recent Events

October 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 19, 2024 at 12:00 PM UTC

at Cantor Global Healthcare Conference

September 5, 2024 at 2:15 PM UTC

at Wells Fargo Healthcare Conference

September 4, 2024 at 8:05 PM UTC

at Morgan Stanley Global Healthcare Conference

September 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 28, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 17, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers